WASHINGTON — Several drugmakers are expected to sign pricing agreements with the Trump administration on Friday, according to four people familiar with the plans, who were not authorized to speak publicly.
The agreements would be the latest in a series of deals in which pharmaceutical companies agree to lower drug prices and invest more domestically in exchange for avoiding tariffs and other benefits, such as fast-tracked drug reviews.
The terms of the deals thus far have remained private, leaving their full impact unknown.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply